SCHEMBL376722

SCHEMBL376722

Cc1nc(Cl)c(Cl)c(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
PDK2 Q15119 3/20 0.38
PDK4 Q16654 1/20 0.38
CYP1A2 P05177 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
PDE10A Q9Y233 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10376639 0.84 LMNA (0.50) LMNATDP1PDK2PDK4
SCHEMBL29484711 0.80 HTT (0.35) LMNATDP1PDK2PDK4PDE10A
SCHEMBL7325343 0.80 LMNA (0.33) LMNATDP1PDK2PDK4
SCHEMBL14165804 0.80 HTT (0.35) LMNATDP1PDK2PDK4PDE10A
SCHEMBL275977 0.79 PDE10A (0.48) LMNATDP1PDK2PDK4L3MBTL1
SCHEMBL10378513 0.76 LMNA (0.31) LMNAPDK2PDK4
SCHEMBL28454443 0.76 PDK2 (0.34) LMNAPDK2PDK4
SCHEMBL10506373 0.74 GOT1 (0.35) LMNAPDK2PDK4
SCHEMBL6718305 0.74 LMNA (0.31) LMNAPDK2PDK4
SCHEMBL28660374 0.74 MBOAT4 (0.32) LMNAPDK2PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115490641-A Synthesis method of 2-methyl-4, 5, 6-trichloropyrimidine 大连大学 2022-12-20 CN claimed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 US disclosed
US-20250027917-A1 SYSTEM FOR AUTOMATED PROCESSING OF MASS SPECTROMETRY SAMPLES AND DATA DELAWARE STATE UNIVERSITY (US) 2025-01-23 US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-20100240536-A1 PYRIMIDIN-4-YLPROPANEDINITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS BAYER CROPSCIENCE AG (DE) 2010-09-23 US disclosed
EP-2229813-A1 Pyrimidine-4-ylpropandinitrile derivatives, method for their manufacture and their use as herbicides and plant growth regulators Bayer CropScience AG (DE) 2010-09-22 EP disclosed
EP-0343752-B1 Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates DOWELANCO (US) 1993-12-01 EP disclosed
US-5163995-A For use with grassy crops and soybeans DOWELANCO (US) 1992-11-17 US disclosed
US-5010195-A From 5-alkoxy-1,2,4-triazolo(1,5-c)pyrimidine THE DOW CHEMICAL COMPANY (US) 1991-04-23 US disclosed
WO-1989011782-A1 ALKOXY-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE-2-SULFONAMIDES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THE DOW CHEMICAL COMPANY (US) 1989-12-14 WO disclosed
EP-0343752-A1 Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates DowElanco (US) 1989-11-29 EP disclosed
EP-0210025-A2 5-Substituted-6-aminopyrimidine derivatives, composition and uses AMERICAN HOME PRODUCTS CORPORATION (US) 1987-01-28 EP disclosed
US-4617393-A CONGESITIVE HEART FAILURE AMERICAN HOME PRODUCTS CORPORATION (US) 1986-10-14 US disclosed
EP-0139248-A2 Reactive dyes BAYER AG (DE) 1985-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 LMNA 2193/4885TDP1 659/4885PDK2 92/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 LMNA 2193/4885TDP1 659/4885PDK2 92/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 LMNA 2193/4885TDP1 659/4885PDK2 92/4885
US-20100240536-A1 PYRIMIDIN-4-YLPROPANEDINITRILE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS DDT, PLPBP, HPD LMNA 3510/4885TDP1 1040/4885PDK2 168/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 LMNA 2199/4885TDP1 649/4885PDK2 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.